Talapro-3 could help move Talzenna into earlier prostate cancer.

First human data on MK-2010 are imminent.

The company’s TRPV1 antagonist looks doomed.

The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April. 

The company admits defeat with zelenectide.

But this comes in second-line breast cancer, a use the group isn’t pursuing.

Varseta-M efficacy wanes, but more than justifies a pivotal trial.

Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.

The company reveals its anti-GPRC5D T-cell engager.

Ascentage hopes to become a new force in BTK.